newsfilter
← Latest News
GlobeNewswire·

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

VTVT
  • vTv Therapeutics Inc. granted 2,500 stock options to a non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).
  • The stock options carry an exercise price of $31.44 per share & a 10-year term.
  • Vesting occurs over 4 years, with 25% vesting on the one-year anniversary & the remainder vesting quarterly over the next 36 months, subject to continued employment.
  • The grant is subject to the terms of the 2026 Inducement Plan & the stock option agreement.
  • Cadisegliatin (TTP399) is a liver-selective glucokinase activator in a US Phase 3 trial for type 1 diabetes & has received FDA Breakthrough Therapy designation.
  • The safety & efficacy of cadisegliatin remain unestablished with no guarantee of regulatory approval or commercial availability.